OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

DStorey

Thankyou.

relative strength index?

Relative to what?

I'll see what a search engine turns up but if you have a moment then feel free to comment.

Down again, like I said the other day I wasn't so confident this time.

Glad I didn't put much in.

When 1 of the drug trials succeeds I'll wish that I'd put more in.

More importantly when not if pipeline comes through we can look at going some way to f@%king cancer.....

Great news out today, share price should now show an upward trend from here - my target 25 by Sept, 32 by next Jan, but who knows?..could see this really shoot soon

Agree strongly very encouraging especially those suffering from Parkinson's.

and motor neuron....

Hope it works

Oxford Bio reaches nerve milestone
By Clive Cookson, Science Editor
Published: June 1 2004 19:20 | Last Updated: June 1 2004 19:20


The prospect of treating spinal injuries through gene therapy will take another step closer to reality on Wednesday when Oxford Biomedica announces that its nerve repair product has restored feeling and movement to animals with damaged limbs.


The Oxford-based company said in December that its scientists had observed regrowth of nerves in rats treated with Innurex.

Nicholas Mazarakis, head of neurobiology, will tell the annual meeting of the American Society of Gene Therapy in Minneapolis on Wednesday that the product has restored function to the injured limbs.

"When I saw the data - how well we were getting back both sensory and motor functions - I was stunned," said Alan Kingsman, chief executive of Oxford Biomedica. "We felt we should repeat the experiments to confirm these exciting results."

The company and its academic partners at King's College London were talking to clinicians about how best to test Innurex in paralysed patients. "I think we could be going clinical in 2006," Prof Kingsman said.

The rats tested were an animal model for "avulsion injury", a common cause of paralysis in sporting and motor accidents, in which nerves are damaged by very rapid stretching or pulling. The Christopher Reeve Foundation - set up by the Hollywood actor paralysed after a riding accident in 1995 - recently gave King's College a grant to explore the use of Innurex in spinal cord injuries similar to the one suffered by Mr Reeve.

Innurex uses a virus to carry a gene called RARbeta2 to injured nerves. This gene - normally active in embryos but not in adults - makes the cells receptive to body chemicals that stimulate the growth of next nerve connections.

Most experiments to repair spinal injuries have not used gene therapy but other techniques including the application of cells or growth factors to the injury. But none has yet given convincingly reproducible results in animal experiments. "Stem cell therapy must be at least 10 years away, even if you take the most optimistic view of the stem cell story," said Prof Kingsman.

Oxford Biomedica has six gene therapy products in pre-clinical development or early clinical trials, either for cancer or to treat damaged nerves or brain cells. Innurex is one of the most promising. The shares closed down p at 16p.

http://news.ft.com/servlet/ContentServer?pagename=FT.com/StoryFT/FullStory&c=StoryFT&cid=1085944439149

RNS Number:2978Z
Oxford Biomedica PLC
02 June 2004


FOR IMMEDIATE RELEASE 2 JUNE 2004


OXFORD BIOMEDICA'S INNUREX(R) PRODUCT RESTORES LIMB FUNCTION IN A PRECLINICAL
MODEL OF AVULSION INJURY


- Data presented at the 7th Annual Meeting of the American Society For Gene
Therapy -


Oxford, UK: 2 June 2004 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that preclinical data from the Innurex nerve repair
programme are being presented by Dr. Nicholas Mazarakis, the Company's Vice
President for Neurobiology, at the 7th Annual Meeting of the American Society of
Gene Therapy held in Minneapolis from June 2-6. The data, which will shortly be
sent for peer-reviewed publication, show that Innurex is able to restore
function to damaged limbs in a model of avulsion (stretch) injury. These results
indicate that Innurex may have clinical benefit in patients with nerve damage
resulting from severe pull/stretch injury, a common consequence of sporting and
motor accidents.

Within the field of neurobiology nerve repair has been a long sought goal for
the treatment of nerve damage and spinal injury. The aim is to induce nerve
cells to regrow and bridge sites of injury thereby reconnecting the nerve fibres
and restoring function. At present there are no effective therapies for nerve
damage and spinal injury.

The new results with Innurex are the first functional data to come from Oxford
BioMedica's nerve repair programme and they indicate that the new nerve
connections induced by Innurex restore substantial function to limbs that have a
damaged nerve supply. The data were generated from an ongoing collaboration
between Oxford BioMedica and Professors Malcolm Maden and Stephen McMahon at
King's College London.

Prof. Alan Kingsman, Oxford BioMedica's Chief Executive, said: "Innurex goes
from strength to strength. In December of last year we announced that Innurex
had been shown to induce nerve regrowth in vivo. We now know that the regrowth
is significant in that injured limbs regain both movement and sensation as a
result of treatment with Innurex."

-Ends-


For further information, please contact:

Oxford BioMedica plc:
---------------------
Professor Alan Kingsman, Chief Executive Tel: +44(0)1865 783 000

City/Financial Enquiries:
-------------------------
Lisa Baderoon/ Mark Court: Buchanan Communications Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
---------------------------------
Sue Charles, Katja Stout: Northbank Communications Tel: +44 (0)20 7886 8150


Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

In addition to its technical expertise in gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing know-how. The development
pipeline includes two novel anti-cancer products in clinical trials and two
neurotherapy products in advanced preclinical development for Parkinson's
disease and retinopathy. The Company is underpinned by an extensive preclinical
and research portfolio and about 70 patent families, which represents one of the
broadest patent estates in the field.

The Company has a staff of approx 65 split between its main facilities in Oxford
and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford
BioMedica has corporate collaborations with Wyeth, Intervet, Merck & Co,
Amersham and Kiadis.

Further information is available at http://www.oxfordbiomedica.co.uk

2. Innurex(R)
Innurex is a product comprising Oxford BioMedica's LentiVector delivery system
carrying the RAR??2 gene (a subtype of the retinoic acid receptor). The Company
acquired exclusive rights to the RAR??2 gene from King's College London where
the initial observation that this gene could programme nerve cells to regrow in
vitro was made. The product is being investigated extensively in in vivo
industry-standard preclinical models of nerve repair in avulsion and spinal cord
injury. In April 2004, the Christopher Reeve Paralysis Foundation awarded a
grant to King's College London to explore the use of Innurex in spinal cord
injury.

3. King's College London

King's is one of the oldest and largest colleges of the University of London
with 13,800 undergraduate students and some 5,300 postgraduates in ten schools
of study. The College had 24 of its subject-areas awarded the highest rating of
5* and 5 for research quality, demonstrating excellence at an international
level. King's is in the top group of five universities for research earnings
with income from grants and contracts of more than #93 million (2002-2003) and
has an annual turnover of #320 million. King's is a member of the Russell Group,
a coalition of the UK's major research-based universities.


This information is provided by RNS
The company news service from the London Stock Exchange

END

Hopefully, we will hang on to the gains this time.

I have come to realise that trying to make sense of the market is not a concern to waste time on.
OXB is one stock that particularly confuses - Government and charity funded as a backup and a well run outfit - and yet it does not hold on to what would appear to be well deserved increases. May be this time eh!

Been following this one for a while and I think the closer we get to one of their major products getting the green light, the more the share will hold on to gains. I agree though that Ox Bio look to be well run but maybe the Invest Chron.'s sell rating a few months ago shook the confidence of many in the long term prospects for the company. However, they keep producing positive newsflow and still have plenty of cash to keep them going. I'm sticking with them for those reasons. The fact their products are likely to improve a lot of lives is also a bonus.

throoking66 - I very much agree with all you say and rather particularly your last sentence. I am in for the long run.

Great find from Gerry2 from the other place
http://www.newscientist.com/news/news.jsp?id=ns99995067

OXFORD BIOMEDICA ACQUIRES CHIRON PATENTS AND
ISSUES SHARES TO CHIRON


Oxford, UK - 7 June 2004: Oxford BioMedica (LSE OXB), the leading gene therapy
company, announced today that it has signed an agreement with the Chiron
Corporation to acquire certain patent families from Chiron's gene therapy patent
portfolio. The agreement includes taking assignment of Chiron's interest in a
license agreement with an undisclosed university. Financial terms have not been
disclosed.

Chiron's patent portfolio contains some early gene therapy technology that
complements Oxford BioMedica's substantial gene therapy patent estate. The
technology acquired includes:

1. The use of human cell lines for the production of gene therapy products

2. Gene-directed enzyme pro-drug therapy (GDEPT)

3. The use of the envelope protein of the vesicular stomatis virus (VSV-g) for
increasing the ability of gene therapy vectors to transduce a broad range
of human cell types

Under a separate agreement also signed today, Chiron has made an equity
investment in Oxford BioMedica subscribing for a total of 316,026 ordinary
shares of 1p each at 17.23 pence per share.

Commenting on these agreements the Company's Senior Vice President for
Commercial Development, Peter Nolan, said: 'We are delighted to have concluded
this agreement with Chiron and welcome them as shareholders in the Company.
Securing this intellectual property will enhance our competitive position in
gene therapy and in the use of our technology in drug discovery.'


-Ends-

http://www.uk-wire.com/cgi-bin/articles/200406071239294760z.html

Thanks Janus

http://www.oxfordbiomedica.co.uk/news/2004-ob-11.htm

another grant, just the bit of good news needed for this stock

Down again,

A little bit lower & I'll buy some more.

05/07/04 09:00 Oxford Biomedica in licence deal with Viragen for LentiVector gene delivery AFX

Oxford Biomedica in licence deal with Viragen for LentiVector gene delivery
AFX

LONDON (AFX) - Oxford Biomedica PLC said it has entered into a licence agreement with Viragen Inc for its LentiVector gene delivery technology.

The agreement provides Viragen with worldwide exclusive rights to utilize the proprietary LentiVector technology in its collaboration with Roslin Institute (Scotland) to develop Avian Transgenic Technology as a novel platform for the efficient and economical manufacturing of therapeutic proteins in chicken eggs.

Under the agreement, Oxford BioMedica will receive an upfront licence fee and annual maintenance payments, the statement added.

In addition, Oxford BioMedica will receive milestone payments on the achievement of technical goals by Viragen and royalties on commercialisation of the Avian Transgenic Technology.

No other financial details were provided.

newsdesk@afxnews.com

http://www.moneyam.com/action/news/showArticle?id=389728

Testing resistance at 20p, needs more volumes to get through that and then it's 23 then 25.